<DOC>
	<DOCNO>NCT01736579</DOCNO>
	<brief_summary>The purpose long-term study provide additional evidence safety efficacy IGIV , 10 % treatment participant Alzheimer´s Disease complete Phase 3 Baxter precursor study 160701 . All participant receive IGIV , 10 % either 0.2 g/kg 0.4 g/kg body weight depend treatment assignment Baxter study 160701 . Participants investigator blind dose unless otherwise notify sponsor .</brief_summary>
	<brief_title>Long-Term Study IGIV , 10 % Alzheimer´s Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<criteria>Main Completed 18 month study treatment assessment Baxter precursor study 160701 Diagnosis probable Alzheimer´s Disease ( AD ) Able comply test infusion regimen ( include adequate correct visual acuity hear ability ) Has caregiver ( study partner ) willing able participate Main Significant neurological disease AD Clinically significant cardiac/cardiovascular problem ( e.g . uncontrolled blood pressure , atrial fibrillation , heart disease , clot disorder , stroke , recent heart attack ) Contraindication undergo MRI ( e.g . pacemaker [ exception MRIcompatible pacemaker ] , severe claustrophobia , ferromagnetic implant metal plate ) Specific finding brain MRI ( microhemorrhages , superficial siderosis , vasogenic edema , macrohemorrhage , major stroke , multiple lacuna ) Active malignancy history malignancy within 5 year prior screen exception follow : adequately treat basal cell squamous cell carcinoma skin , carcinoma situ cervix , stable prostate cancer require treatment Uncontrolled major depression , psychosis , major psychiatric disorder ( ) Poorly control diabetes Serious problem liver kidney Known history hypersensitivity follow infusion human blood blood component ( e.g . human immunoglobulins human albumin ) Current recent treatment immunomodulatory therapy ( exception immunoglobulin nonsystemic lowdose systemic corticosteroid ) Recent use investigational drug biologics , include aim alter AD progression ( exception immunoglobulin ) Active immunization treatment AD time There reason might appropriate participate trial . Please contact Medical Information medinfo @ baxter.com detail .</criteria>
	<gender>All</gender>
	<minimum_age>51 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>